A functional link between polo-like kinase 1 and the mammalian target-of-rapamycin pathway?

Cell Cycle

Volumn 9, Issue 9, 2010, Pages 1690-1696

  Renner, Annelies G ^a,b   Créancier, Laurent ^b   Dos Santos, Cédric ^a   Fialin, Camille ^a   Recher, Christian ^a,c   Bailly, Christian ^b   Kruczynski, Anna ^b   Payrastre, Bernard ^a,c   Manenti, Stéphane ^a  

^a CHU PURPAN   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Cell cycle; Cell growth; G1 phase; Leukemia; Mitosis; mTOR pathway; Polo like kinase; Therapeutic target

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; POLO LIKE KINASE 1;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CELL CYCLE REGULATION; CELL GROWTH; LYMPHOMA; MITOSIS; NONHUMAN; REVIEW;

MAMMALIA;

EID: 77953589376     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.9.11295     Document Type: Review

References (51)

1. Barr F, Silljé H, Nigg E. Polo-like kinases and the orchestration of cell division. Nature Rev Mol Cell Biol 2004; 5:429-40. (Pubitemid 38745493)
2. Van de Weerdt B, Medema R. Polo-like kinases. A team in control of the division. Cell Cycle 2006; 5:853-64.
3. Winkless J, Alberts G. Differential regulation of polo-like kinases 1, 2, 3 and 4 gene expression in mammalian cells and tissues. Oncogene 2005; 24:260-6.
4. Takai N, Hamanaka R, Yoshimatsu J, Mivakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005; 24:287-91.
5. Strebhardt K, Ullrich A. Targeting Polo-like kinase 1 for cancer therapy. Nat Rev Canc 2006; 6:321-30.
6. Gumireddy K, Reddy R, Cosenza S, Boominathan R, Baker SJ, Papathi N, et al. ON01910, a non-ATP-competitive small molecular inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005; 7:275-86. (Pubitemid 40568686)
7. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, et al. BI2536, a potent and selective inhibitor of Polo like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17:316-22.
8. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 2009; 69:6969-77.
9. Yim H, Erikson R. Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation. Mol Cell Biol 2009; 29:2609-21.
10. Trenz K, Errico A, Costanzo V. Plx1 is required for chromosomal DNA replication under stressful conditions. EMBO J 2008; 27:876-85.
11. Lei M, Erikson R. Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint. Oncogene 2008; 27:3935-43.
12. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100:5789-94.
13. L during pironetin-induced apoptosis. Oncogene 2009; 28:107-16.
14. Rizki A, Mott J, Bissell M. Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res 2007; 67:11106-10.
15. Liu X, Lei M, Erikson R. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26:2093-108.
16. Lu LY, Wood J, Minter-Dykhouse K, Ye L, Saunders T, Yu X, Chen J. Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol 2008; 28:6870-6.
17. Sun D, Luthra P, Li Z, He B. PLK1 downregulates parainfluenza virus 5 gene expression. Plos Pathol 2009; 5:525-9.
18. Mito K, Kashima K, Kikuchi H, Daa T, Nakayama I, Yokohama S. Expression of Polo-like kinase (PLK1) in non-Hodgkin's lymphoma. Leuk Lymph 2005; 46:225-31.
19. Renner A, Dos Santos C, Recher C, Bailly C, Creancier L, Kruczynski A, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemias and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009; 114:659-62.
20. Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009; 23:1564-76.
21. 2/M checkpoint in acute myelocytic leukaemia. Eur J Pharmacol 2008; 591:102-5.
22. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mansat-De Mas V, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105:2527-34. (Pubitemid 40387055)
23. Recher C, Dos Santos C, Demur C, Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 2005; 4:1540-9.
24. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103:253.
25. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15:807-26.
26. Hidalgo M, Rowinsky EK. The rapamycin-sensitive transduction pathway as a target for cancer therapy. Oncogene 2000; 19:6680-6. (Pubitemid 32197708)
27. Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grünwald V, Weiss G, Hidalgo M. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003; 9:2887-92. (Pubitemid 36993245)
28. Memmott R, Dennis P. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signalling 2009; 21:656-64.
29. Ma X, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10:307-18.
30. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C. A critical role for Lyn in acute myeloid leukemia. Blood 2008; 111:2269-79. (Pubitemid 351451434)
31. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10:457-68.
32. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-8.
33. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-101.
34. Petersen J, Nurse P. TOR signaling regulates mitotic commitment through the stress MAP kinase pathway and he Polo and cdc2 kinases. Nature Cell Biol 2007; 9:1-10.
35. Hartmuth S, Petersen J. Fission yeast Tor1 functions as part of TORC1 to control mitotic entry through the stress MAPK pathway following nutrient stress. J Cell Sci 2009; 122:1737-46.
36. Schonbrun M, Laor D, Lopez-Maury L, Bähler J, Kupiec M, Weisman R. TOR complex 2 controls gene silencing, telomere length maintenance, and survival under DNA-damaging conditions. Mol Cell Biol 2009; 29:4584-94.
37. Astrinidis A, Senapedis W, Henske E. Hamartin, the tuberous sclerosis complex 1 gene product, interacts with Polo-like kinase 1 in a phosphorylation-dependent manner. Hum Mol Genet 2006; 15:287-97.
38. Fingar D, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled b mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002; 16:1472-87. (Pubitemid 34686329)
39. Fingar D, Richardson C, Tee A, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1 eukaryotic translation initiation factor 4E. Mol Cell Biol 2004; 24:200-16. (Pubitemid 38010048)
40. Rosner M, Fuchs C, Siegel N, Valli A, Hengstschläger M. Functional interaction of mTOR complexes in regulating mammalian cell size and cell cycle. Hum Mol Genet 2009; Epub ahead of print.
41. Didier C, Cavelier C, Quaranta M, Galcera MO, Demur C, Laurent G, et al. G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress. Oncogene 2008; 27:3811-20. (Pubitemid 351862053)
42. Nappi T, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M. Identification of polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 2009; 69:1916-23.
43. Astrinidis A, Senapedis W, Coleman T, Henske E. Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase1/cyclin B. J Biol Chem 2003; 278:51372-9.
44. Liu X, Erikson RL. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci USA 2002; 99:8672-6.
45. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996; 135:1701-13.
46. Smith E, Proud C. Cdc2-cyclin B regulates eEF2 kinas activity in a cell cycle- and amino acid-dependent manner. EMBO J 2008; 27:1005-16. (Pubitemid 351508149)
47. Zhao M, Auerbach A, D'Costa A, Rapoport A, Burger A, Sausville E, et al. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cll lymphoma combination therapy. Clin Cancer Res 2009; 15:1708-20.
48. Zhao X, Gartenhaus R. Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma. Expert Opin Ther Targets 2009; Epub ahead of print.
49. Matthew E, Hart L, Astrinidis A, Navaraj A, Dolloff N, Dicker D, et al. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle 2009; 8:4168-75.
50. Nakajima H, Toyoshima-Morimoto F, Taniguchi E, Nishida E. Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. J Biol Chem 2003; 278:25277-80.
51. Lowery DM, Clauser KR, Hjerrild M, Lim D, Alexander J, Kishi K, et al. Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 2007; 26:2262-73.